CRISPR THERAPEUTICS AG Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
CRISPR THERAPEUTICS AG (CRSP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $28.51 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-02-12
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $28.51, a 26.20% decline from fiscal 2024.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $38.63, a 36.07% increase from fiscal 2023.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $28.39, a 26.34% decline from fiscal 2022.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $38.54, a 50.19% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|
| 2025-12-31 | $28.51 10-K · filed 2026-02-12 | |
| 2024-12-31 | $38.63 10-K · filed 2026-02-12 | |
| 2023-12-31 | $28.39 10-K · filed 2026-02-12 | |
| 2022-12-31 | $38.54 10-K · filed 2025-02-11 | |
| 2021-12-31 | $77.38 10-K · filed 2024-02-21 | |
| 2020-12-31 | $42.28 10-K · filed 2023-02-21 | |
| 2019-12-31 | $24.57 10-K · filed 2022-02-15 | |
| 2018-12-31 | $33.82 10-K · filed 2021-02-16 | |
| 2017-12-31 | $11.16 10-K · filed 2020-02-12 | |
| 2016-09-30 | $7.68 10-Q · filed 2016-11-22 | |
| 2015-09-30 | $3.01 10-Q · filed 2016-11-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |